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BACKGROUND. The aim of this collaborative study was to compare the long term 
results of hepatic resection (Hx) with those of orthotopic liver transplantation 
(OLTx) in large numbers of cirrhotic patients with hepatocellular carcinoma (HCC) 
and to delineate the roles of these two surgical treatments. 
METHODS. The databases of the National Cancer Center Hospital in Japan and the 
University of Pittsburgh Medical Center in the U. S. were exchanged and 294 
cirrhotic patients who underwent curative Hx and 270 cirrhotic patients who 
underwent curative OLTx were selected for comparison. 
RESULTS. The mortality rate within 30 days and that within 150 days after Hx were 
Significantly lower than those after OLTx (P '" 0.001 and P = 0.00007, respectively). 
Overall survival was similar between the Hx group and the OLTx group (P = 0.40). 
When compared in the HCC patients without macroscopic vascular invasion and 
lymph node metastases, the overall survival rate after OLTx was significandy higher 
than that after Hx (P '" 0.006). However, this difference was not significant between 
the patients with Child-Pugh Grade A tumors in the Hx group and all patients 
(majority with Child-Pugh Grade C tumors) in the OLTx group (P '" 0.25J. Tumor 
free survival after OLTx was significantly higher {han that after Hx (P < 0.0001). 
particularly in HCCs measuring ::;5 em, unilobarly distributed tumors. and HCCs 
with either no or only microscopiC vascular invasion. In HCCs measuring> 5 cm 
and those with macroscopic vascular invasion, the tumor free survival rate was 
similar between the Hx group and the OLTx group. 
CONCLUSIONS. In the face of organ shortage, HCC developing in a well compen-
sated cirrhotic liver initially may be treated with Hx. However. the authors believe 
OLTx should be applied selectively to those patients with tumor recurrence andlor 
progressive hepatic failure. Cancer 1999;86:1151-8. 
© 1999 American Cancer Society. 
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S everai effective therapeutic options for hepatocellular carcinoma (HCCI have become available in recent years. Among them are 
regional chemoembolization, I percutaneous alcohol injection.:! cryo-
surgicalJ or microwave ablation, I subtotal hepatectomy (hepatic re-
section). :;·11 and totai hepatectomy with liver replacement (orthotopic 
liver transplantation I. 12·16 
The outcome after hepatic resection (Hx) for HCC and that of 
orthotopic liver transplantation (OLTx) have been debated in several 
reports but without definite conclusions regarding the difference in 
long term survival. '7 . 20 In addition. each report contained only a 
limited number of early stage HCC tumors in patients with cirrhotic 
livers treated by Hx because of the smail numbers of such cases in the 
Western countries. Therefore. {he database of the National Cancer 
Center Hospital (Tokyo. Japanl and that of the University of Pitts-
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burgh Medical Center (Pittsburgh. PAl were ex-
changed to compare the long term overall and tumor 
free survival rates between Hx and OLTx in a large 
number of cirrhotic patients with HCC. 
MATERIALS AND METHODS 
Hepatic Resection Group 
Between 1985 and 1994. 723 patients underwent pri-
mary Hx for the treatment of HCC at the National 
Cancer Center Hospital (NCCH). Tokyo. Japan. Por-
tions of this experience were reported previously. 10.21 
Among these 723 patients. 403 (55.7%) had histologi-
cally proven concomitant cirrhosis. Resection of the 
tumor(s) was incomplete in 109 patients (27.0%) (58 
patients had microscopic exposed tumors. 5 patients 
had positive surgical margins at the tumor thrombus 
in the portal vein. 45 patients underwent debulking 
resection due to limited liver function. and 1 patient 
had extrahepatic disease that was not removed). The 
remaining 294 cirrhotic patients (72.9%) who under-
went complete resection of the tumors were selected 
for this study. The range of the follow-up period was 
0.23-140 months (median. 46.0 months). The preop-
erative level of serum a-fetoprotein ranged from 0.1-
376.200 ng/mL (mean. 2094 ng/mLl. The surgical pro-
cedure was comprised of 2 trisegmentectomies (0.7%). 
8 bisegmentectomies (2.7%). 30 segmentectomies 
(10.2%). 57 subsegmentectomies (19.4%). and 197 
nonanatomic limited resections (less extensive than 
subsegmentectomyl (67.0%). The details of the surgi-
cal techniques were reported previously.lo During the 
same period. no liver transplantation was performed 
at either NCCH or in Japan. 
Orthotopic Liver Transplantation Group 
Between 1981-1997. 307 patients underwent OLTx in 
the presence of HCC at the University of Pittsburgh 
Medical Center (Pittsburgh. PA). Portions of this expe-
rience were reported previously.III.2:! Of the 307 trans-
planted patients. 283 (92.1%) had concomitant cirrho-
sis. Thirteen of the 283 patients (4.6%) had 
microscopic positive margins due to extrahepatic ex-
tension of the rumor. The remaining 270 cirrhotic 
patients who underwent complete removal of the tu-
morts) bv OLTx were selected for the study. The fol-
low-up period ranged from 3-201 months (median. 
36.6 months). Eighty-seven patients (32.2%) had HCCs 
that were undetected preoperativelv. Cyclosporine 
and steroids were lIsed as immunosuppressive ther-
apy between 1981-1989: tacrolimus replaced cyclo-
sporine beginning at the end of 1989. Immunosup-
pressive therapy and the OL Tx technique were 
descnbed previously.':.!·:!' One hundred and one pa-
tients underwent hepatic resection for HCC between. 
1980-1997 at Pittsburgh University Hospital. 
Patient Characteristics 
The patients' characteristics are shown in Table 1. The 
mean age of the patients was lower in the OLTx group 
and the incidence of viral hepatitis as the etiology of 
the cirrhosis was higher in the Hx group. Although 
there was no significant difference in the mean tumor 
size (P = 0.08). tumors measuring ::::;2 cm and those 
measuring >5 cm in greatest dimension were more 
frequent in the OLTx group than in the Hx group. The 
OLTx patients had significantly more bilobar tumors 
compared with Hx patients. The overall incidence of 
vascular invasion was similar between the two groups; 
however. macroscopic vascular involvement was ob-
served more frequently in the OLTx group (17.7%) 
than in the Hx group (7.2%). With regard to the histo-
logic differentiation of HCC. the Hx group contained 
more patients with poorly differentiated tumors than 
the OLTx group. When stratified according to the 
pTNM staging system.25 >66% of the Hx patients were 
classified as Stage II and Stage IlIA. whereas patients 
in the OLTx group were evenly distributed into Stage I. 
Stage II-IlIA. and Stage IVA. The OLTx group included 
more patients with poor hepatic functional reserve 
(Child-Pugh Grade C) than the Hx group. 
Statistical Analysis 
The Statistical Package for Social Science software 
(SPSS. Inc .• Chicago. IL) was used for data analysis. 
The Kaplan-Meier product-limit method with the log 
rank test was used to evaluate tumor free and patient 
survival rates for various prognostic factors. Results 
were reported as the mean :!: the standard error of the 
mean (SE). Significance levels were set at P < 0.05. 
RESULTS 
Surgical Mortality and Short Term Results 
Four patients in the Hx group died within 1 month 
after surgery (surgical mortality rate: 1.4%) and an 
additional 8 patients died during the initial hospital 
stay (in-hospital mortality rate: 4.1 %). Nine patients 
(3.1 %) died of hepatic failure. 2 patients (0.7%) died of 
cardiopulmonary complications. and 1 patient (0.3%) 
died of tumor recurrence. A total of 17 patients (5.8%) 
died within 150 days after resection. 
[n the OLTx group. 22 patients died within 1 
month of transplantation (surgical mortality rate: 
7.8%1. Forty-nine patients (1 i.3%) died within ISO 
days after transplantalion of various complications 
not related to HCC. 
Resection versus Transplantation for HCC In Cirrhosis/Yamamoto et II. 1153 
TABLE 1 
Characteristics of the Patients Who Underwent Hepatic Resection and Those of Patients Who Underwent Uver 
Transplantation 
Hepatic resection Uver transplantation 
FadDr (n = 294) (n = 270) Pvaluea 
Age (yrs) 
Mean:!: SE 59.7:!: 7.5 54.5 :!: 11.6 < O.OOlb 
::;60 171 (58.2%) 178 (65.9%) 0.06 
>60 123 (41.6%) 92 (34.1%) 
Gender 
Male 219 (74.5%) 202 (74.6%) 0.93 
Female 75 (25.5%) 68 (25.2%) 
Etiology of cirrhosis 
Hepatitis B 50 (17.0%) 57 (21.1%) 
Hepatitis C 145 (49.3%) 17 (6.3%) 
NonA. NonB' 36 (12.2%) 77 (28.5%) 
Alcoholic 46 (17.0%) 
Metabolic diseases 20 (7.4%) 
Others 63 (21.4%) 53 (19.6%) 
Size of tumor (cm) 
::;2cm 71 (24.1%) 125 (46.3%) < 0.00001 
2-5 cm 163 (62.3%) 96 (35.6%) 
>5cm 40 (13.6%) 49 (l8.1%) 
No. of tumors 
Single 165 (56.1%) 144 (53.3%) 0.51 
Multiple 129 (43.9%) 126 (46.7%) 
Lobar involvement 
Unilobar 286 (97.3%) 197 (73.0%) < 0.00001 
Bilobar 8 (2.7%) 73 (27.0%) 
Vascular invasion 
Absent 171 (58.2%) 160 (59.3%) 0.00004 
Microscopic 110 (37.4%) 72 (26.7%) 
Macroscopic 13 (4.4%) 38 (14.1%) 
Histologic differenuationJ 
WeU 26 (10.4%) 55 (23.2%) < 0.00001 
Moderate 166 (66.4%) 166 (70.0%1 
Poor 56 (23.2%) 16 (6.8%) 
Lymph node metastases 
Ailsent (NO) 293 (99.7%) 265 (96.1%) 0.07 
Present (N 11 1(0.3%) 5 (1.9%) 
pTNM Stage 
I 44 (15.0%) 65 (31.5%) < 0.00001 
II 85 (28.9%) 47 (17.4%) 
IlIA 133 (45.2%) 51 (18.9%) 
IlIB 1 (0.3%) 2 (0.7%) 
IVA 31 (10.5%) 65 (31.5%) 
Child classification 
A 193 (65.6%) 10 (3.7%) < 0.00001 
B 97 (33.0%) 19 (7.0%) 
C 4 (1.4%) 241 (89.3%) 
SE: standard error . 
.• The slllllIticance ollhe dltTerence was lesled tar each parameter bv the Mantel-Haensul cht·square test. 
h The avera~e ages were compared bva two'lalled Student I test tar paIred data . 
• These pauentS Included those w1Ih VIral hepalllls before the test tor the hepallus C 11 rus was IVllIable. 
d The dati r~ardln~ hlSIOIOflC differtnU3uon 01 Ihe hepatocellular carcinomas were not avarJable for •• pauenrs ff4K9~F in the hepallc reseeuon In 33 patIents 
; ) 22,\\1 in (he OrthOtOPIC lover lransplant.allon troup. 
_" __ ~D __ ~ .. ___ ' ___ • _ ... .a.J • __ ........ _ 
. ~ 
A 
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FIGURE 1. (a) Overall patient survival rates were Similar between the hepatic 
resection (Hx) group (n = 294) and the orthotopic liver transplantation (lx) 
group (n = 270) (p =0.40) but (b) tumor free survival rates were significantly 
higher In the Tx group compared with the Hx group (P < 0.0001). 
Overall Patient Survival and Tumor Free Survival Rates 
The I-year. 3-year. 5-year. and lO-year overall cumu-
lative survival rates after Hx were 88.7%. 70.8%. 47.1 %. 
and 24.4%, respectively. and were 75.6%. 63.1%. 
54.5%. and 36.2%. respectively. after OLTx (Fig. la). 
There was no significant difference in overall survival 
(P = 0.40). 
During the follow-up period. 176 of 294 patients in 
the Hx group (59.9%) and 53 of 270 patients in the 
OLTx group (19.6%) developed tumor recurrence. Cu-
mulative I-year. 3-year. 5-year. and 7-year tumor free 
survival rates in the OLTx group were 75.2%. 63.1%. 
53.9%. and 44.4%. respectively. and were 67.8%. 
24.1%. 14.3%. and 7.2%. respectively. in the Hx group 
(Fig. 1 b). The difference was statistically significant 
(P < O.OOOll . 
Prognostic Factors 
The influence of various prognostic factors on overall 
and tumor free survival is shown in Table 2. The 
overall survival rate was significantly better in the 
OLTx group than in the Hx group for solitary tumors . 
unilobarly distributed tumors, and for tumors with 
microscopic vascular invasion_ The overall survival 
rate of the OLTx group also was significantly higher 
than that of the Hx group with regard to patients with 
pTNM Stage II tumor(s) or those with fair liver func-
tion (Child-Pugh Grade B). However. survival after Hx 
was significantly higher for the patients with tumors 
with macroscopic vascular invasion . 
The tumor free survival rate of the OLTx group 
was significantly higher than that of the Hx group for 
tumors measuring s5 em, unilobarly distributed tu-
mors, tumors with no or only microscopic vascular 
invasion. and tumors of well or moderate histologic 
differentiation (Table 2). However. when the tumors 
measured >5 cm or had macroscopic vascular inva-
sion or poorly differentiated histology, there was no 
statistically significant difference in tumor free sur-
vival between the Hx and the OLTx groups. Lymph 
node status could not be analyzed because lymph 
node metastasis was so rare for both groups (one case 
in the Hx group and five cases in the OLTx group). 
Specific Comparisons 
The majority of liver transplantation centers no longer 
consider patients for OLTx if the HCC invades the 
major vascular branches or regional lymph nodes or if 
the patient has distant metastases. Overall and tumor 
free survival rates for the patients with tumors without 
macroscopic vascular invasion. regional lymph node 
metastases. or distant metastases were compared be-
tween 287 patients in the Hx group and 230 patients in 
the OLTx group (Figs. 2a and 2b). In this subgroup of 
patients both the overall and tumor free survival rates 
in the OLTx group were significantly higher than those 
in the Hx group. 
Uver transplantation primarily is the treatment of 
hepatic failure. Should HCC in those patients with well 
compensated cirrhosis be treated with transplanta-
tion? To answer this question. 193 patients in the Hx 
group with good hepatic function (Child-Pugh Grade 
A) without macroscopic vascular invasion. regional 
lymph node metastases. or distant metastases were 
selected. The overall and tumor free survival rates of 
193 patients in the Hx group was compared with that 
of 230 patients in the OLTx group (all Child-Pugh 
grades) with the same tumor characteristics (Le .• no 
macroscopic vascular invasion. regional lymph node 
metastases. or distant metastases). As shown in Fig-
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TABLE 2 
Univariate Analysis of Prognostic Factors for Patient and Tumor Free Survival Rates 
Patient surviYal (mean In months :t SID Tumor free survival (mean In montlu :t SID 
LMr LMr 
Hepalic resection tranrplantatlon Hepalic resection tranrplantatloa 
Factor (n = 294) (n = 270) pvahJel (n = 294) (n = 270) pftlue" 
Age (yrs) 
~SM 70.6:!: 3.9 99.6 :!: 8.4 0.69 32.1 :!: 21 14O.7:!: 9.5 <0.0001 
>60 60.9 :!: 4.5 58.7 ± 51 0.80 32.3 :!: 3.0 931:!: 4.8 <0.0001 
Gender 
Male 71.4 :!: 3.6 76.9:!: 5.7 0.40 33.4: 21 114.5 :!: 7.3 <0.0001 
Female 53.0:!:U 1141:!: 12.6 0.002 29.9:!: 31 164.6:!: 10.5 <0.0001 
Size of tumor (em) 
~O 69.9:!: 5.6 85.5 :!: 6.2 0.14 35.5 :!: 3.4 13U:!: 6.4 <0.0001 
2-5 68.1 :!: 3.9 10s.4:!: 10.4 019 30.6 :!: 2.1 14O.7:!: 10.4 <0.0001 
>5 551:!: 7.2 48.0 :!: 8.7 0.09 32.9 :!: 6.1 651:!: 12.9 0.76 
No. of tumors 
Single 71.4 :!: 4.0 1181:!: 10.4 0.02 37.7 :!: 2.6 175.4 :!: 9.1 <0.0001 
Multiple 62.9 :!: 4.8 69.1 :!: 7.1 0.31 25.7 :!: 2.5 IOS.1 :!: 8.7 <0.0001 
Lobar involvement 
Unilobar 671 :!: 3.1 112.0 :!: 8.1 0.01 32.8 :!: 1.9 173.6:!: 7.1 <0.0001 
SHobar 72.5 :!: 18.7 42.9:!: 4.5 012 21.6 :!: 4.4 49.3 :!: 5.6 013 
Vascular invasion 
Absent 761:!: 4.0 113.5:!: 9.0 0.19 37.7 :!: 2.3 180.6:!: 8.2 <0.0001 
MicroscopIC 56.3 :!: 4.7 89.7:!: 10.8 0.05 261:!: 2.9 121.6 :!: 11.2 <0.0001 
Maaoscopic 39.9 :!: 9.0 20.4:!: 4.0 0.04 13.4:!: 2.5 19.0 :!: 4.5 0.51 
Histologic differentiationb 
Well 6.37 :!: 0.52 6.52:!: 0.62 0.98 312:!: 0.38 8.75 :!: 0.25 <0.0001 
Moderate 5.62 :!: 0.33 6.09:!: 0.44 0.92 2.47 :!: 0.18 8.64:!: 0.45 <0.0001 
Poor 4.08 :!: 0.42 5.65 :!: 1.79 0.55 2.90 :!: 0.38 8.OS :!: 2.36 014 
pTNM Stage 
I 74.6:!: 6.2 82.2 :!: 5.9 0.38 39.7 :!: 4.3 113.8:!: 3.3 <0.0001 
11 70.4:!: 4.9 133.8 :!: 14.4 0.02 35.5 :!: 3.1 <0.0001 
lilA 621:!: 4.6 100.8 :!: 12.1 0.11 30.9 :!: 3.0 142.3 :!: 12.0 <0.0001 
IlIB 2.38 :!: 2.0 0.23 4.4 :!: 1.1 
IVA 55.0 :!: 8.7 40.5 :!: 4.0 0.28 22.0:!: 4.4 46.0:!: 5.1 0.006 
Child classification 
A 75.8 :!: 4.0 112.3 :!: 26.7 0.72 37.5:!: 2.5 1191:!: 29.2 0.06 
B 51.2:!: 3.9 83.1 :!: 12.5 0.03 23.8 :!: 2.1 l001:!: 12.3 <0.0001 
C 35.4 :!: 12.9 93.4 :!: 7.2 0.13 13.5:!: 3.5 148.8:!: 7.7 <0.0001 
SE: standard error . 
• The si~lhcance althe difference was tested for each sub~up by the 10g!1ni test. 
h Analyses were perfonned for the patienl.l WIth data available regardmg histologic differenuation. 
. Value could not be computed because all obseMtions were ceruoled II a maJimum of 201 monthlh.e .. no teC1Ilm1Ce 0CtIIIred1. 
" Induded only 1 case and could 1101 be computed because all obsemuons were ceruoled at a lIIUIIIIum of 65.3 monlhs h.e .. no pltienl diedl. 
"ncluded onlv 1 case and could nOI be rompuled because all obsemuons VIm censoled II a maJimum of 65.3 monlhs h.e .. no recurrence occumdl. 
ures 3a and 3b, overall survival after Hx in this sub-
group was similar to that after OLTx (P = 0.25), al-
though the tumor free survival rate was significantly 
lower in the Hx group (P < 0.0001). 
DISCUSSION 
Subtotal hepatectomy or hepatic resection is used to 
treat HCC of limited number and size in patients with 
compensated cirrhosis. Total hepatectomy and liver 
replacement or OLTx primarily is the treatment of 
choice for hepatic failure although it can be used to 
treat HCCs of any number and size even in patients 
with decompensated cirrhosis. The prognosis of pa-
tients with advanced stage HCC (HCC with macro-
scopic vascular invasion. lymph node involvement, 
and distant metastases) is very poor after either he-
patic resection or transplantation.17.18.26.27 
In this study. two large series of HCC patients with 
cirrhosis treated by different surgical strategies at in-
stitutions in Japan and the U. S. were compared ret-
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FIGURE 2. Both (a) patient survival rates and (b) tumor free survival rates 
were significantly higher in OrthOtOPIC liver transplant (Tx) group compared with 
the hepatiC resection (Hx) group (P = 0.006 and P < 0.0001. respectively) 
when the patients with good risk hepatocellular carcinoma (pTNM Stages I. II. 
iliA. and IVA without macroscopic vascular invasion) were selected. 
rospectively. There was a difference in the etiology 
and hepatic functional reserve between the two 
groups. The OLTx group was comprised more of early 
stage and advanced stage tumors than the Hx group 
based on the comparison of maximum tumor size. 
vascular invasion. and pTNM stage. As mentioned 
earlier. OLTx can be used to treat HCCs of any number 
and size. OLTx patients treated for end-stage liver 
disease occasionally have early stage tumors undetec-
ted by preoperative examination. When the patients 
are selected according to established criteria for ap-
propriate treatment in one institution. there should be 
no overlapping of patients between each treatment 
group. In Western nations. transplamation has been 
chosen for many cirrhotic patiems with HCC. for 
whom major hepatic resection was impossi.ble due to 
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FIGURE 3. (a) Patient survival rates of patients With Child-Pugh Grade A 
disease in the hepatic resection (Hx) group (n = 193) were similar (P = 025) 
to those of the patients With mostly Ctlild-Pugh Grade C disease in the 
orthotopic liver transplantation (Tx) group (n = 230) when patients with good 
risk hepatocelluar carcinoma were selected. but (b) the tumor free survival 
rates were significantly higher In Tx group compared with the Hx group (P < 
0.0001). 
limited liver function. Among 101 patients treated by 
hepatic resection at Pittsburgh University Hospital 
during the same period. 69 patients (68.3%) had non-
cirrhotic livers. 51 patients (50.5%) had pTNM Stage III 
tumors. and 38 patients (38%) had pTNM Stage IV 
tumors. In addition 82 patients (81.1%) underwent 
major hepatic resection. However. in Asian countries. 
especially fapan. in which early stage HCC is diag-
nosed through routine physical examination for those 
patients with chronic liver disease. resection has been 
performed widely for cirrhotic patients with tumors by 
limited liver resection. Thus. Japanese patients with 
HCC and cirrhosis who are treated by hepatic resec-
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tion should overlap ~th those Western patients with 
similar diseases treated by transplantation. 
Our study reconfirmed the findings of other re-
ports that in patients with early stage HCC (HCC with-
out macroscopic vascular invasion. lymph node in-
volvement. or distant metastases). hepatic resection 
can provide excellent survival for those patients with 
good liver function,8.10.11 but the incidence of tumor 
recurrence after resection is extremely high when 
compared with that after transplantation.14-19 Should 
this then lead to the conclusion that all early stage 
HCC patients should be treated with transplantation 
regardless of hepatic function? As indicated in this 
study and others. 13.17 surgical and perioperative mor-
tality is significantly higher after transplantation than 
after hepatic resection. The overall survival rate actu-
ally was higher for the initial 3-4 years after hepatic 
resection than transplantation (Fig. 3a). despite the 
higher incidence of tumor recurrence after resection 
(Fig. 3b). 
In the Hx group the patients with recurrent HCC 
were treated effectively with reresection (20 patients). 
ethanol injection (18 patients). and chemoemboliza-
tion (87 patients)' or a combination thereof. Con-
versely. the recurrent tumors in the OLTx group were 
widespread and rarely could be treated by regional 
therapy. The mean survival after tumor recurrence 
was 31.6 :t 21.5 months (mean :t SE) in the Hx group 
and 15.3 :t 14.5 months (mean := SE) in the OLTx 
group (P < 0.001). Tumor growth under immunosup-
pression appeared to be accelerated.21l 
Within 5 years. 143 patients died after resection 
and 114 patients died after transplantation. One hun-
dred of the 143 patients (69.9%) died with tumor re-
currence after resection. and 41 of the 114 patients 
(36.0%) patients died after transplantation. After 5 
years. 35 patients died after resection and 17 patients 
died after transplantation. Ten of the 35 patients 
(28.6%) in the Hx group and 13 of the 17 patients 
(76.5%) patients in the OLTx group died free of rumor. 
Thus. the incidence of death unrelated to HCC was 
significantly higher in transplantation group than in 
the resection group both within and after 5 years (P < 
0.00001 and P = 0.001. respectively). The cirrhotic 
HCC patients who were treated by hepatic resection 
most often died with HCC ur of the complications of 
hepatic failure and portal hypertension. When those 
patients were treated by liver transplantation. the 
deaths related to HCC ur cirrhosis could be avoided 
either largely or entirely. However. the mortality in-
herent to transplantation. such as death due to infec-
tion and rejection. still affected the survival rates. 
Liver transplantation should be avoided in HCC 
pauents with macroscopic vascular invasion. J\'mph 
node involvement. or distant metastases. 18.19 Hepatic 
resection for HCC in patients with concomitant cir-
rhosis should be limited to patients with good hepatic 
function. Tumor recurrence should be monitored very 
closely after resection. and recurrent tumors should 
be treated aggressively with reresection, chemical or 
thermal ablation. and/or arterial chemoembolization. 
With this approach the survival of patients with good 
hepatic function should be as good as that of patients 
who undergo liver transplantation. as indicated in this 
study. When liver function begins to deteriorate 
and! or when the recurrent tumors appear to be better 
treated by liver replacement. liver transplantation may 
be considered. Longitudinal therapeutic planning (he-
patic resection followed by aggressive regional therapy 
as described earlier and liver transplantation) may 
improve survival further for the patients with HCC 
with compensated cirrhosis. We believe patients with 
fair or poor liver function are best treated with liver 
transplantation. providing the HCC does not invade 
major branches of hepatic vessels and does not have 
lymph node or distant metastases. In the face of organ 
shortage, the use of liver transplantation for HCC 
should be limited to good risk patients as indicated in 
this study and others.lHo 
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